Predicting Effective Therapy in Pancreatic Cancer

Running, not enrolling

Conditions studied: Pancreatic Cancer, Pancreatic Adenocarcinoma

In brief

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Key facts

Study ID

NCT03033927

Run by

Memorial Sloan Kettering Cancer Center

People needed

74

Starts

2017-01-24

Expected to finish

2027-01-24

Last updated by the study team

2026-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
• Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
• Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
• ECOG performance status 0-2.
• A minimum age of 18 years old.

You may not qualify if…

• Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
• Known to be HIV positive on antiretroviral therapy
• Prior organ allograft
• Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

Where it is running

• Memorial Sloan Kettering Cancer Center Basking Ridge — Basking Ridge, New Jersey, United States
• Memorial Sloan Kettering Cancer Center @ Suffolk — Commack, New York, United States
• Memorial Sloan Kettering Westchester — Harrison, New York, United States
• Memorial Sloan Kettering Nassau — Uniondale, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.